喘息治療薬の世界市場 - 2025～2032年

喘息治療薬の世界市場は、2024年に257億2,000万米ドルに達し、2032年には376億2,000万米ドルに達すると予測され、予測期間2025年のCAGRは5.2％で成長します。

喘息は、世界中で数百万人が罹患している蔓延性の慢性炎症性疾患です。多くの場合、予定外のヘルスケア受診につながり、学校や仕事を休むことになります。喘息は、様々な要因によって引き起こされる環境アレルギーに似た不適切な免疫反応を特徴とします。この反応は気管支の過反応を引き起こし、気道の収縮、平滑筋のリモデリング、粘液産生の増加を引き起こします。

慢性喘息を効果的に管理し、症状を緩和しながら増悪の頻度を減らすために、β2作動薬、抗コリン薬、吸入コルチコステロイド、長時間作用性β作動薬（LABA）、ロイコトリエン受容体拮抗薬、テオフィリン、クロモリン、ジレトン、モノクローナル抗体など、いくつかのクラスの薬剤が利用できます。

急性喘息増悪の場合は、炎症を速やかに抑え呼吸を改善するためにオーラルコルチコステロイドが処方されることもあります。全体として、このような様々な治療法を駆使したオーダーメイドのアプローチは、喘息患者の生活の質を著しく向上させます。こうした要因が、世界の喘息治療薬市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

喘息の有病率の増加

喘息の有病率の増加は、世界の喘息治療薬市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予測されています。

喘息は世界的に数百万人が罹患する慢性呼吸器疾患であり、約2億6,000万人がコントロール不良の喘息に苦しんでいます。喘息の有病率は、特に中低所得国（LMICs）で増加しています。

米国における喘息の疫学

American College of Allergy, Asthma &Immunologyの2024年のデータによると、米国人の約7.7％が喘息であり、約2,490万人が喘息患者であり、そのうち大人が2,020万人、子供が460万人です。喘息の有病率は成人では顕著に高く、推定8.0％が罹患しているのに対し、小児では6.5％です。さらに、喘息は男性（6.2％）よりも女性（9.7％）に多いです。

喘息患者のヘルスケア利用は著しく、年間約94,000件の入院と900,000件以上の救急外来受診が報告されています。喘息の経済的負担は大きく、その費用は毎年500億米ドルに達すると推定されています。喘息は深刻な健康リスクももたらし、年間3,500人以上が死亡し、その約3分の1が65歳以上の高齢者です。最近の統計によると、喘息患者の約半数が毎年少なくとも1回の喘息発作を経験しており、成人（39.6％）は小児（38.7％）よりも発作を起こしやすいです。

喘息の症状は、アレルゲン（花粉やダニなど）、空気中の刺激物質（煙や化学物質の煙など）、異常気象、運動、呼吸器疾患など、さまざまな要因によって引き起こされる可能性があります。驚くべきことに、CDCによると、現在喘息を患っている成人の約60％、小児の44％が症状をコントロールできていないといいます。これらすべての要因が、世界の喘息治療薬市場に需要をもたらしています。

世界の喘息治療薬市場の臨床試験

さらに、業界の主要企業は、喘息治療薬市場の成長を促進する臨床試験や政府の取り組みに力を入れています。例えば、2024年5月、GSK plc社は、血中好酸球数の上昇によって示される2型炎症を特徴とする重症喘息を患う成人および青年を対象としたデペモキマブの有効性および安全性を評価した第III相臨床試験、SWIFT-1およびSWIFT-2の良好な結果を発表しました。

また、2022年6月、米国立衛生研究所（NIH）は、デュピルマブと呼ばれるモノクローナル抗体の、コントロール不良のアレルギー性喘息の小児における喘息発作の軽減と肺機能の改善に対する有効性を評価する臨床試験を開始しました。この臨床試験は、特に喘息増悪率が高い都市部の低所得地域に住む小児を対象としています。この試験のタイトルは『Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents』（PANDA）です。これらすべての要因が、世界の喘息治療薬市場に需要をもたらしています。

さらに、生物製剤の進歩に対する需要の高まりも、世界の喘息治療薬市場の拡大に寄与しています。

薬剤の副作用

薬剤の副作用は、喘息治療薬の世界市場の成長を妨げるでしょう。喘息治療薬は病状を管理するために不可欠ですが、患者のアドヒアランスに影響を与える副作用を引き起こす可能性もあります。吸入コルチコステロイドは、気道の炎症を抑える効果があるため、喘息管理によく処方されます。口腔鵞口瘡（カンジダ症）、嗄声、咽頭痛、咳嗽などがあります。口腔鵞口瘡は真菌感染症で、口腔内に白い斑点や痛みを引き起こすことがあります。

LABAは喘息の症状を抑えるために使用されますが、心拍数の増加や動悸などの潜在的なリスクを伴います。まれに、ICSを併用せずにLABAを使用すると、重度の喘息増悪につながることがあります。ロイコトリエン受容体拮抗薬は、気分の変化や消化器症状を引き起こします。短時間作用型β-アゴニスト（SABA）は心拍数を増加させ、振戦、低カリウム血症（カリウム値の低下）を過剰使用により起こすことがあります。従って、上記の要因が世界の喘息治療薬市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 喘息の罹患率の増加
  • 抑制要因
    • 薬の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 薬剤クラス別

• 吸入コルチコステロイド
  • フルチカゾン
  • ブデソニド
  • モメタゾン
  • ベクロメタゾン
  • シクレソニド
  • その他
• ロイコトリエン修飾薬
  • モンテルカスト
  • ザフィルルカスト
  • ジレウトン
  • その他
• 長時間作用型ベータ刺激薬（LABA）
  • サルメテロール
  • フォルモテロール
  • その他
• 即効性のある薬
  • アルブテロール
  • レバルブテロール
  • その他
• 複合吸入器
  • フルチカゾンとサルメテロール
  • ブデソニドとフォルモテロール
  • モメタゾンとフォルモテロール
  • フルチカゾンとビランテロール
  • その他
• 生物学的製剤
  • ベンラリズマブ
  • デュピルマブ
  • メポリズマブ
  • レスリズマブ
  • テゼペルマブエッコ
  • その他
• その他

第7章 投与経路別

• 吸入
• オーラル
• その他

第8章 流通チャネル別

• 病院薬局
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• AstraZeneca
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Amgen Inc.
• Covis Pharma
• Camber Pharmaceuticals, Inc.

第12章 付録

The global asthma drugs market reached US$ 25.72 billion in 2024 and is expected to reach US$ 37.62 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2025-2032.

Asthma is a prevalent, chronic inflammatory condition that affects millions of individuals worldwide. It often leads to unplanned healthcare visits and results in missed school and workdays. Asthma is characterized by an inappropriate immune response, similar to environmental allergies, triggered by various factors. This response causes bronchial hyperreactivity, leading to airway constriction, smooth muscle remodeling, and increased mucus production in the airways.

To effectively manage chronic asthma and alleviate symptoms while reducing the frequency of exacerbations, several classes of medications are available beta-2 agonists, anticholinergics, inhaled corticosteroids, long-acting beta-agonists (LABAs), leukotriene receptor antagonists, theophylline, cromolyn, zileuton, monoclonal antibodies and among others.

In cases of acute asthma exacerbations, oral corticosteroids may be prescribed to quickly reduce inflammation and improve breathing. Overall, a tailored approach utilizing these various treatment options can significantly enhance the quality of life for individuals living with asthma. These factors have driven the global asthma drugs market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Asthma

The Increasing Prevalence of Asthma is significantly driving the growth of the global asthma drugs market and is expected to drive throughout the market forecast period.

Asthma is a prevalent chronic respiratory disease affecting millions globally, with approximately 260 million people suffering from poorly controlled asthma. The increasing prevalence of asthma, particularly in low- and middle-income countries (LMICs).

Asthma Epidemiology in the U.S.

According to the American College of Allergy, Asthma & Immunology data in 2024, approximately 7.7% of Americans have asthma, translating to roughly 24.9 million individuals, of which 20.2 million are adults and 4.6 million are children. The prevalence of asthma is notably higher in adults, with an estimated 8.0% affected, compared to 6.5% in children. Additionally, asthma is more common among females (9.7%) than males (6.2%).

Patients with asthma experience significant healthcare utilization, reporting around 94,000 hospital inpatient stays and over 900,000 emergency department visits annually. The economic burden of asthma is substantial, with estimated costs reaching $50 billion each year. Asthma also poses serious health risks, resulting in more than 3,500 deaths annually, nearly one-third of whom are aged 65 or older. Recent statistics indicate that about half of individuals with asthma experience at least one asthma attack each year, with adults (39.6%) being more likely to have an attack than children (38.7%).

Asthma symptoms can be triggered by various factors, including allergens (such as pollen and dust mites), irritants in the air (like smoke and chemical fumes), extreme weather conditions, exercise, or respiratory illnesses. Alarmingly, about 60% of adults and 44% of children with current asthma have uncontrolled symptoms according to the CDC. All these factors demand the global asthma drugs market.

Global Asthma Drugs Market Clinical Trials

Furthermore, key players in the industry more focus on clinical trials and government initiatives that would drive this asthma drugs market growth. For instance, in May 2024, GSK plc announced positive results from the Phase III clinical trials, SWIFT-1 and SWIFT-2, which evaluated the efficacy and safety of depemokimab in adults and adolescents suffering from severe asthma characterized by type 2 inflammation, indicated by elevated blood eosinophil counts.

Also, in June 2022, the National Institutes of Health (NIH) initiated a clinical trial to evaluate the efficacy of a monoclonal antibody called dupilumab in reducing asthma attacks and improving lung function in children with poorly controlled allergic asthma. This trial specifically targets children living in low-income urban neighborhoods, who often face higher rates of asthma exacerbations. The study is titled Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents, or PANDA. All these factors demand the global asthma drugs market.

Moreover, the rising demand for advancements in biologics contributes to the global asthma drugs market expansion.

Adverse Effects of Drugs

The adverse effects of drugs will hinder the growth of the global asthma drugs market. While asthma medications are essential for managing the condition, they can also lead to adverse effects that may impact patient adherence. Inhaled corticosteroids are commonly prescribed for asthma management due to their effectiveness in reducing airway inflammation. These include oral thrush (candidiasis), hoarseness, sore throat, and cough. Oral thrush is a fungal infection that can cause white patches and soreness in the mouth.

LABAs are used to control asthma symptoms but come with potential risks including increased heart rate and palpitations. In rare cases, using LABAs without concomitant ICS can lead to severe asthma exacerbations. Leukotriene receptor antagonists mood changes and gastrointestinal symptoms. Short-acting beta-agonists (SABAs) increase heart rate, tremors, and hypokalemia (low potassium levels) can occur with excessive use. Thus, the above factors could be limiting the global asthma drugs market's potential growth.

Segment Analysis

The global asthma drugs market is segmented based on drug class, route of administration, distribution channel, and region.

Drug Class:

The inhaled corticosteroids segment is expected to dominate the global asthma drugs market share

The inhaled corticosteroids segment holds a major portion of the global asthma drugs market share and is expected to continue to hold a significant portion of the global asthma drugs market share during the forecast period.

Inhaled corticosteroids (ICS) are the FDA-recommended first-line treatment for preventing asthma exacerbations in patients with persistent asthma. Persistent asthma is defined by symptoms that occur more than twice a week, more than three nighttime awakenings per month, frequent use of short-acting beta-2 agonists for symptom control, or any limitations on normal activities due to asthma.

Regular use of ICS significantly reduces the frequency of asthma symptoms and bronchial hyper-responsiveness, lowers the risk of severe exacerbations, and enhances the overall quality of life for patients. This activity will explore the mode of action of inhaled corticosteroids, including their pharmacological mechanisms, potential adverse effects, eligible patient populations, monitoring requirements, and the essential role of the interprofessional healthcare team in managing patients with asthma.

Inhaled corticosteroids exert their effects by binding to glucocorticoid receptors in the airway epithelial cells. This binding leads to a cascade of anti-inflammatory actions, including the inhibition of pro-inflammatory cytokines and chemokines, reduction of airway inflammation, and decreased mucus production. As a result, ICS helps restore normal airway function and reduce asthma symptoms.

Furthermore, key players in the industry product launches and approvals that would drive this asthma drugs market growth. For instance, in October 2023, Aiolos Bio, a newly launched biotechnology company, raised $245 million in a Series A financing round to develop a novel asthma treatment that requires administration only twice a year. This significant funding marks one of the largest venture capital rounds for a biotech company in recent months and positions Aiolos Bio as a promising player in the respiratory therapeutics market.

Also, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, was approved by the FDA as the first and only rescue medication for asthma that can be used on an as-needed basis to reduce the risk of exacerbations. This innovative inhaler combines albuterol, a short-acting beta-2 agonist (SABA), with budesonide, an inhaled corticosteroid (ICS), providing a dual-action approach to asthma management. These factors have solidified the segment's position in the global asthma drugs market.

Geographical Analysis

North America is expected to hold a significant position in the global asthma drugs market share

North America holds a substantial position in the global asthma drugs market and is expected to hold most of the market share.

Asthma is a chronic inflammatory respiratory condition that affects approximately 262 million people worldwide, including around 25 million in the United States. Patients with asthma often experience recurrent symptoms such as breathlessness and wheezing, which can vary significantly in severity and frequency over time. Regardless of the severity of their condition, adherence to treatment, or level of symptom control, these patients remain at risk for severe exacerbations.

Globally, there are an estimated 136 million asthma exacerbations each year, with about 10 million occurring in the U.S. These exacerbations can pose serious physical threats and have significant emotional impacts on patients, sometimes leading to fatal outcomes. The prevalence is particularly high among adults, with about 8.0% affected, and among children, where around 7.0% suffer from the condition. This high prevalence creates a substantial demand for effective asthma medications.

There is a growing awareness of asthma and its management among healthcare providers and patients. Increased education about asthma symptoms and treatment options has led to improved diagnosis rates, driving demand for asthma medications. Many patients are now more proactive in seeking treatment, leading to earlier intervention and better management of the disease.

The North American market is characterized by rapid advancements in asthma therapeutics, including the development of new inhaled corticosteroids, biologics, and combination therapies. Innovations such as monoclonal antibodies targeting specific inflammatory pathways have transformed asthma management, offering more effective options for patients with severe or uncontrolled asthma.

Furthermore, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and innovative launches would drive this asthma drugs market growth. For instance, in July 2023, Viatris announced the launch of Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, marking it as the first FDA-approved generic version of Symbicort for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch is significant as it provides a more affordable option for patients managing these common respiratory conditions. Thus, the above factors are consolidating the region's position as a dominant force in the global asthma drugs market.

Asia Pacific is growing at the fastest pace in the global asthma drugs market share

Asia Pacific holds the fastest pace in the global asthma drugs market and is expected to hold most of the market share.

The increasing incidence of asthma in the Asia-Pacific region is a major factor driving market growth. Urbanization, environmental pollution, and lifestyle changes contribute to higher asthma rates, particularly in developing countries. The growing population and increased exposure to allergens and irritants amplify the demand for effective asthma medications.

Asthma affects over 34 million people in India, leading to thousands of deaths annually. According to the Global Burden of Disease report by the Institute for Health Metrics and Evaluation (IHME), asthma accounts for 27.9% of disability-adjusted life years (DALYs) in the Indian population. This statistic highlights a concerning trend, as asthma-related mortality in India is approximately three times higher and DALYs are twice as high compared to the global averages for asthma.

The report further reveals that India contributes significantly to global asthma fatalities, with around 46% of all asthma deaths occurring within the country. Approximately 200,000 individuals succumb to asthma-related complications each year, underscoring the urgent need for effective management and treatment strategies.

There has been substantial progress in developing new asthma therapies, including biologics and combination treatments that offer improved efficacy and safety profiles. The commercialization of biologics, which have demonstrated effectiveness in clinical trials with fewer side effects, enhances treatment options for patients with severe asthma.

Furthermore, key players in the region have innovative launches and government initiatives that would drive this asthma drugs market. For instance, in February 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in individuals aged 12 years and older whose condition is not adequately controlled with existing therapies. This approval marks Japan as the first country in the world to approve Dupixent specifically for CSU, highlighting its significance as a novel treatment option for patients with unmet medical needs.

Also, in June 2022, Glenmark Pharmaceuticals announced the launch of a novel fixed-dose combination (FDC) drug for patients with uncontrolled asthma in India. The new product, branded as Indamet, combines indacaterol and mometasone to provide an effective treatment option for individuals struggling to manage their asthma symptoms. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global asthma drugs market.

Competitive Landscape

The major global players in the asthma drugs market include AstraZeneca, GSK plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Amgen Inc., Covis Pharma, and Camber Pharmaceuticals, Inc. among others.

Key Developments

• In January 2024, AstraZeneca announced that AIRSUPRA (albuterol/budesonide) is now commercially available in the United States by prescription. This medication received FDA approval for the as-needed treatment or prevention of asthma symptoms and to help prevent sudden severe breathing problems, also known as asthma attacks, in individuals aged 18 years and older.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global asthma drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Asthma
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects of Drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Inhaled Corticosteroids *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Fluticasone
  • 6.2.4. Budesonide
  • 6.2.5. Mometasone
  • 6.2.6. Beclomethasone
  • 6.2.7. Ciclesonide
  • 6.2.8. Others
• 6.3. Leukotriene Modifiers
  • 6.3.1. Montelukast
  • 6.3.2. Zafirlukast
  • 6.3.3. Zileuton
  • 6.3.4. Others
• 6.4. Long-Acting Beta Agonists (LABAs)
  • 6.4.1. Salmeterol
  • 6.4.2. Formoterol
  • 6.4.3. Others
• 6.5. Quick-Relief Medications
  • 6.5.1. Albuterol
  • 6.5.2. Levalbuterol
  • 6.5.3. Others
• 6.6. Combination Inhalers
  • 6.6.1. Fluticasone and Salmeterol
  • 6.6.2. Budesonide and Formoterol
  • 6.6.3. Mometasone and Formoterol
  • 6.6.4. Fluticasone and Vilanterol
  • 6.6.5. Others
• 6.7. Biologics
  • 6.7.1. Benralizumab
  • 6.7.2. Dupilumab
  • 6.7.3. Mepolizumab
  • 6.7.4. Reslizumab
  • 6.7.5. Tezepelumab-ekko
  • 6.7.6. Others
• 6.8. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Inhalation*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospital Pharmacies
• 8.4. Retail Pharmacies
• 8.5. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. AstraZeneca*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. GSK plc
• 11.3. Teva Pharmaceutical Industries Ltd.
• 11.4. Merck & Co., Inc.
• 11.5. Regeneron Pharmaceuticals, Inc.
• 11.6. Sanofi
• 11.7. Amgen Inc.
• 11.8. Covis Pharma
• 11.9. Camber Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us